微信公众号

官网二维码
中国癌症防治杂志

中国癌症防治杂志 ›› 2019, Vol. 11 ›› Issue (1): 62-67.doi: 10.3969/j.issn.1674-5671.2019.01.11

• 临床研究 • 上一篇    下一篇

SOX方案联合阿帕替尼一线治疗晚期胃癌的临床研究

  

  1. 新疆维吾尔自治区人民医院肿瘤科; 伊犁州新华医院肿瘤科；新疆维吾尔自治区人民医院皮肤科
  • 出版日期:2019-02-25 发布日期:2019-03-28
  • 通讯作者: 王芳 E-mail：7wangfangxj@163.com。
  • 基金资助:
    国家自然科学基金项目（81660514）

Efficacy of first-line SOX chemotherapy plus Apatinib for advanced gastric cancer patients

  • Online:2019-02-25 Published:2019-03-28

PDF (PC)

464

赞

摘要： 目的 观察替吉奥、奥沙利铂联合阿帕替尼在晚期胃癌一线治疗中的临床疗效。方法 选择2015年2月至2016年10月于新疆维吾尔自治区人民医院就诊的晚期胃癌患者88例，随机分为试验组和对照组，每组44例。对照组给予替吉奥联合奥沙利铂（SOX方案）化疗，试验组在对照组的基础上应用阿帕替尼，比较两组患者的近期疗效、不良反应及生存情况。结果 试验组患者的客观缓解率明显高于对照组（40.91% vs 20.45%，χ2=4.238，P=0.037），疾病控制率与对照组比较差异无统计学意义（86.36% vs 70.45%，χ2=3.289，P=0.070）。试验组中位总生存期较对照组长（12个月 vs 9.5个月，χ2=4.254，P=0.039），中位无疾病进展生存期亦较对照组长（9个月 vs 6个月，χ2=8.815，P=0.003）；试验组高血压和手足综合征总发生率高于对照组（P＜0.05），其余不良反应发生率差异无统计学意义（P＞0.05）。结论 替吉奥和奥沙利铂联合阿帕替尼一线治疗晚期胃癌患者可取得较好的临床疗效，能有效延长患者的生存期和疾病进展时间，且安全性良好。

关键词: 胃肿瘤, 替吉奥, 奥沙利铂, 阿帕替尼, 疗效, 安全性

Abstract: Objective To observe the clinical efficacy of Tiggio（S-1），Oxaliplatin plus Apatinib as first-line treatment for patients with advanced gastric cancer. Methods Eighty-eight patients with advanced gastric cancer who were admitted to the Xinjiang Uygur Autonomous Region people's Hospital from February 2015 to October 2016 were enrolled. They were randomly divided into the control group （44 cases） and the experimental group （44 cases）. The control group was given S-1  combined with oxaliplatin chemotherapy（SOX），while the experimental group was given SOX plus Apatinib. Short-term efficacy，adverse reactions，overall survival and progression-free survival of the two groups were compared. Results The objective remission rate in the experimental group was significantly higher than that in the control group （40.91% vs 20.45%，χ2=4.238，P=0.037）. There was no significant difference in disease control rate between the two groups （86.36% vs 70.45%，χ2=3.289，P=0.070）. The median over survival of the experimental group was signicantly longer than that of the control group（12 months vs 9.5 months，χ2=4.254，P=0.039）. The median progression-free survival was also significantly longer than that of the control group （9 months vs 6 months，χ2=8.815，P=0.003）. The total incidence of hypertension and hand-foot syndrome in the experimental group was higher than that in the control group（P<0.05），and the incidence of other adverse reactions was not statistically significant（P＞0.05）. Conclusion SOX plus Apatinib as first-line treatment for advanced gastric cancer patients has demonstrated good clinical efficacy. It is safe and can effectively prolong the survival time and disease free progression time .

Key words: Gastric neoplasms, Tiggio, Oxaliplatin, Apatinib, Efficacy, Safety

中图分类号: 

  • R735.2